Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Shares, Down 7.5 Percent, Retreat From Gains on Euro Patent News

NEW YORK, Nov. 29 (GenomeWeb News) - Shares in Nanogen slid 7.45 percent Tuesday afternoon in heavy volume after closing up more than 22 percent yesterday following news that the company's SynX subsidiary had won a European patent.

 

The stock was trading at $4.47 on the Nasdaq exchange mid-Tuesday, down from the $4.83 it reached on Monday afternoon. More than 2.4 million shares traded hands--a 285-percent increase over the average share volume for the past three months.

 

The patent, called "Method for Diagnosing and Distinguishing Stroke," covers a "diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and," Nanogen said in a statement. The IP is also designed to show "whether it was an ischemic or hemorrhagic cerebral event."

 

In October the US Patent and Trademark Office granted SynX a patent for "similar claims" related to the "rapid, point-of-care stoke diagnostic test that the company is developing for emergency medicine."

 

The patent covers a method and a diagnostic kit for analyzing the levels of proteins released from the brain during a neurovascular event. "By measuring the presence of an ischemic marker protein such as a myelin basic protein, S100 protein, neuronal specific enolase, or similar molecules, and a brain endothelial membrane protein such as thrombomodulin or a similar molecule, a physician can determine the occurrence of a stroke," Nanogen said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more